Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) has been assigned a $13.00 price objective by investment analysts at HC Wainwright in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 155.40% from the stock’s current price.

A number of other equities analysts have also issued reports on INO. Citigroup assumed coverage on shares of Inovio Pharmaceuticals in a research report on Friday, October 6th. They set a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. Royal Bank of Canada assumed coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 target price on the stock. Finally, ValuEngine lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Hold” and an average target price of $19.16.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at $5.09 on Tuesday. Inovio Pharmaceuticals has a one year low of $4.09 and a one year high of $9.86. The firm has a market cap of $513.78, a price-to-earnings ratio of -4.24 and a beta of 2.75.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. Inovio Pharmaceuticals’s quarterly revenue was down 79.2% compared to the same quarter last year. equities research analysts forecast that Inovio Pharmaceuticals will post -1.12 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. BlueCrest Capital Management Ltd bought a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter worth about $107,000. Virginia Retirement Systems ET AL bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $101,000. Neuberger Berman Group LLC bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $115,000. Engineers Gate Manager LP bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $117,000. Finally, Emerald Advisers Inc. PA grew its holdings in shares of Inovio Pharmaceuticals by 84.0% in the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 9,280 shares during the last quarter. 32.11% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2018/01/25/inovio-pharmaceuticals-ino-given-a-13-00-price-target-at-hc-wainwright.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply